US Patent 8124611 Inhibitors of the mutant form of kit
Patent 8124611 was granted and assigned to Novartis on February, 2012 by the United States Patent and Trademark Office.
All edits
Edits on 21 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+235 characters)
Article
Patent abstract
The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT is administered.
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08124611 Inhibitors of the mutant form of kit US Patent 8124611 Inhibitors of the mutant form of kit
Infobox
Patent Number
0812461100
Patent Number
812461100
Edits on 22 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
081246110
Date of Patent
February 28, 2012
0Patent Application Number
127001060
Date Filed
February 4, 2010
0Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
081246110
Date of Patent
February 28, 2012
0Patent Application Number
127001060
Date Filed
February 4, 2010
0Patent Primary Examiner
Edits on 14 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08124611 Inhibitors of the mutant form of kit
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08124611
Date of patent
February 28, 2012
Patent application number
12700106
Date Filed
February 4, 2010
Patent primary examiner
Find more entities like US Patent 8124611 Inhibitors of the mutant form of kit
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
